Preclinical studies are essential for the development of innovative therapeutics. In addition to understanding the risk related to the toxicity of a drug candidate, those studies help to analyze and understand accurately its pharmacological properties in a model mimicking the complexity of the human body. Thus, preclinical studies can provide information on the efficacy and pharmacokinetics of the drug, which are essential to better define the conditions of use in trials in humans.
Remarkably, drugs and medical devices for respiratory diseases are growing, given the aging of the population and the increase in the incidence of these diseases. The treatment market for respiratory diseases such as asthma and chronic obstructive pulmonary disease represents more than 60 billion dollars worldwide. Respiratory medical devices would be worth more than $ 50 billion in 2018.
However, CRO companies with specific expertise in the field of respiratory health are rare, particularly in Europe. Accordingly, Cynbiose Respiratory aims to become the preclinical CRO reference for non-regulatory studies to help pharmaceutical and biotechnology industries as well as institutional structures to develop drugs, (including biotherapeutics), and / or medical devices in the field of respiratory diseases.
Our in-depth and broad knowledge in preclinical animal models (ranging from non-human primates to rodents) related to respiratory diseases as well as our expertise in aerosol therapy will help to accelerate your drug development.
More specifically, we offer customized development solutions that are aimed to respond to the needs of our clients and to provide them advices, taking advantage of our extensive study experience in:
- Respiratory tract infections (viral, bacterial and fungal) and vaccine development;
- Chronic inflammatory lung diseases (e.g. COPD, cystic fibrosis, idiopathic pulmonary fibrosis,…);
- Lung cancer;